Tag: Compass Pathways - Page 5 - Psychedelic Alpha

Read more about the article COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

Post published:February 24, 2022
Post category:Press Release

Read more about the article COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

Post published:February 17, 2022
Post category:Press Release

Read more about the article Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

Post published:January 19, 2022
Post category:Press Release

Read more about the article COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Post published:January 4, 2022
Post category:Press Release

Read more about the article COMPASS Selected for Addition to NASDAQ Biotechnology Index

COMPASS Selected for Addition to NASDAQ Biotechnology Index

Post published:December 17, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces changes in Executive Team

COMPASS Pathways announces changes in Executive Team

Post published:December 16, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Post published:December 13, 2021
Post category:Press Release

Read more about the article Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Post published:December 4, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Post published:December 1, 2021
Post category:Press Release

Read more about the article COMPASS Pathways granted fifth US patent for crystalline psilocybin

COMPASS Pathways granted fifth US patent for crystalline psilocybin

Post published:November 23, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.